Key Takeaways
- Record quarter, portfolio shift working: Specialty and CMS each hit their highest-ever revenues (~Rs. 96 cr and ~Rs. 97 cr), validating the strategic pivot toward higher-margin business.
- Gross margin expansion is the core story: A deliberate improvement in business mix drove a continued increase in gross margin, a trend management expects to persist.
- Prime segment remains a drag: Subdued Levetiracetam volumes, with no clear recovery timeline, and muted Mirtazapine performance weighed on the legacy portfolio.
- Investment cycle is ongoing: Other expenses stepped up to a ~Rs. 63 cr run-rate to fund R&D and manufacturing capabilities, a level management says is the new normal.
- What to watch next quarter: Whether the Q2 business mix and momentum prove sustainable, any clarity on Levetiracetam recovery, and progress on Unit III’s path to breakeven.
Portfolio Transformation & Margin Story
- Mix shift delivering results: The focus on improving business mix led to a continued increase in gross margin, with the shift toward high-margin Specialty and CMS segments expected to keep driving this trend.
- Specialty segment peaks: Clocked its highest-ever revenues at ~Rs. 96 crores, driven by products like Donepezil, Ezetimibe, Paliperidone, and Apixaban.
- CMS segment surges: Delivered highest revenues at ~Rs. 97 crores, over 40% YoY growth, fueled by molecules moving to commercial stage and new customer traction from executing difficult late-stage projects.
- Margin caution flagged: Management explicitly warned that business mix, raw material prices, or Forex could negatively impact margins in the future, even as the current trajectory is positive.
Saharsh Davuluri: "we must remain cautious about how business mix, raw material prices or even Forex could negatively impact these margins in the future"
Prime Segment Headwinds
- Levetiracetam volume decline: Customers reduced volumes, creating a headwind; management sees similar cycles in the past and considers it a short-to-medium-term concern, not a long-term structural issue.
- Recovery timeline unclear: Management is not clear on how and when a recovery will happen, calling it "a little bit of a concern," though they expect it to return sooner or later.
- Mirtazapine muted: Performance was subdued compared to last year because tenders that boosted the prior period did not repeat; management expects tenders may occur later in the year.
- Rest of Prime stable: The remainder of the Prime portfolio is performing well and moving as per budgeted numbers.
Saharsh Davuluri: "for us it remains a little bit of a concern because we are not very clear in terms of how and when we will recover."
Unit III Ramp-Up & Operating Leverage
- Utilization growing gradually: Unit III is ramping up well and supporting growth, with late-stage CMS projects being scaled up there; operating leverage is expected to continue kicking in as products scale.
- Breakeven by year-end: Unit III has not yet broken even, but management expects it to be in a good position by the end of the year.
- Capacity is a moving target: Management declined to quantify utilization rate, noting the company is constantly investing in and expanding Unit III and adding products, so capacity continues to evolve.
Pipeline: Peptides, Deuterated Molecules & NCEs
- Peptide progress (Liraglutide, Semaglutide): Significant lab progress made, but DMF filing is on hold until the right formulation partner is found; more molecules have been added to the peptide portfolio, with good customer interest.
- Tirzepatide traction: Seeing good interest for the recently approved molecule; small development quantities expected to go out over the next 12 to 18 months, but the commercial opportunity is a long-term bet.
- Deuterated molecules emerging: Over the last 6 months, a fairly significant number of deuterated clinical candidates have appeared; management believes more deuterated drugs will reach the market in the years to come.
- NCE timelines compressing: Timelines from preclinical/Phase-1 to commercial are gradually reducing, especially as US companies become more aggressive in development post-COVID.
- CMS commercialization path: At least 2 to 3 molecules are expected to get commercialized in the next year or two, with a steady transition from development to commercial contributing to CMS revenue growth.
Sajeev E. Medikonda: "from a commercial perspective this is a long-term bet both for us as well as our customers."
Investment Cycle & Cost Base
- Other expenses step up: The increase to ~Rs. 63 cr (from a Rs. 55-56 cr run-rate) reflects continued investments in R&D and manufacturing capabilities for new product developments, not a one-off.
- New normal on spend: This higher level of other expenses is expected to continue on an ongoing basis.
- Scientific talent investment: Scaling CMS and Specialty APIs is more challenging than Prime APIs due to limited prior information; the company is investing in scientific talent and infrastructure like FBR, RC1, and poly blocks for crystallization studies to address delays and challenges seen in the last 1-2 years.
Saharsh Davuluri: "I would not shy away from admitting the details of the challenge, however, I think that is an area that we are also investing a lot of time and resources on."
Competitive Landscape & Strategy
- European CDMO competition: Management observed at CPHI that European CDMOs are actively getting business from biotech and big pharma and are creating capacities; this is expected to be a continued challenge, especially when competing for European company business.
- US advantage may hold: The company may still have an advantage when competing for US company business against European peers.
- Long-term supply base view: Management sees European and Indian API companies becoming the formidable supply base for most pharmaceutical markets worldwide, framing the competitive dynamic as an opportunity reflected in current and future investments.
- Selective screening ambition: In the long term, the company wants to become more selective in screening for business, focusing on assets that add more value, though currently screening is done only a little bit, not extensively.
Sucheth Davuluri: "...I think it is going to be the European API companies and the Indian API companies that are going to become the formidable supply base for most of the pharmaceutical markets across the world, so I think we are seeing it as an opportunity, our investments reflect that and our investments of the future will also reflect the same."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Gross margin trajectory | Portfolio mix shift to continue driving higher gross margins | Ongoing |
| Unit III breakeven | Expected to be in a good position | By end of this year |
| CMS commercialization | At least 2 to 3 molecules to get commercialized | Next year or two |
| Other expenses run-rate | ~Rs. 63 cr level to continue on an ongoing basis | Ongoing |
| Tirzepatide development quantities | Small development quantities expected to go out | Next 12 to 18 months |
| Q3 business mix | Expected to be similar to Q2 | Q3 FY23 |
Key Metrics
| Metric | Q2 FY23 |
|---|---|
| Total income (H1 FY23) | ₹515.6 cr, up 11.8% YoY |
| Gross margin | 56.2%, vs 53.4% in Q1 FY23 and 49.2% in Q2 FY22 |
| EBITDA (H1 FY23) | ₹98.4 cr, up 39.1% YoY from ₹70.7 cr in H1 FY22 |
| EBITDA margin (H1 FY23) | 19.1%, vs 15.3% in H1 FY22 |
| Profit after tax | ₹38.3 cr, vs ₹20.3 cr in Q2 FY22 |
| EPS | ₹29.9 per share |
| Specialty segment revenue | ~₹96 cr, highest ever |
| CMS segment revenue | ~₹97 cr, highest ever, growth of over 40% YoY |
| Prime segment revenue share | 30% of total revenues |
| Other expenses | ~₹63 cr, up from ₹55-56 cr run rate in prior 4 quarters |
| Cash and cash equivalents | ₹5.3 cr on balance sheet at end of period |
| CMS pipeline: preclinical assets added | 3 or 4 added in Q2 |
| CMS pipeline: Phase-1 assets added | 1 or 2 added in Q2 |
| NCE pipeline: total projects | ~87 odd projects across close to 30 to as many as 50 customers |